重组抗人CD3单抗(SP34-2) | Syd Labs PA007196
Syd Labs体内实验级重组抗人CD3单克隆抗体(克隆号SP34-2)，小鼠IgG1 Kappa（货号：PA007196）是用哺乳动物细胞生产的重组抗体，适用于体外和体内研究，纯度>95%。Syd Labs PA007196不变区为小鼠Mouse IgG1 Kappa (mIgG1或m1)，可与重组小鼠IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007196 |
|---|---|
| 产品名称 | 重组抗人CD3单抗(SP34-2) | Syd Labs PA007196 |
| 英文名 | In Vivo Grade Recombinant Anti-human CD3 Monoclonal Antibody (Clone: SP34-2), Mouse IgG1 Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 分化簇3，CD3D，CD3E，CD3G |
| 概述 | Syd Labs提供重组小鼠 IgG1同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | SP34-2 |
| 同种型 | 小鼠 IgG1 kappa |
| 免疫源 | 抗人CD3单抗(克隆号: SP34-2)是用哺乳动物细胞生产的 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人CD3单克隆抗体(克隆号SP34-2)，小鼠IgG1 Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007196 Syd Labs提供重组小鼠 IgG1同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受人CD3蛋白影响的生物学途径的测定。 |
文献
重组抗人CD3单抗(克隆号：SP34-2)，体内实验级（In Vivo Grade Recombinant Rat IgG2a Isotype Control Antibody，Syd Labs PA007143）
抗人 CD3 单克隆抗体（克隆号：SP34-2）是 SP34 的衍生克隆，已知可与人及非人灵长类动物（包括狒狒、恒河猴、食蟹猴和猪尾猕猴）的大部分外周血淋巴细胞发生交叉反应。与人在体内的对应作用类似，SP34-2 抗体能特异性识别非人灵长类动物的大部分 CD3 阳性细胞，但与单核细胞或粒细胞无交叉反应。
SP34-2 单抗常用于流式细胞术（FC），以鉴定和分析人类及多种非人灵长类物种中的 CD3 阳性细胞。此外，它还可用于刺激多种灵长类动物外周血单核细胞（PBMC）的细胞增殖。
抗人CD3单抗（SP34-2）部分引用文献:
1. Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases
Meng X, et al. Nat Commun. 2024 Mar 9;15(1):2158. PMID: 38461145
“Autoreactive B cells play a central pathogenic role in many autoimmune diseases, highlighting the need for targeted depletion strategies. This study developed bi-specific autoantigen-T cell engagers designed to selectively redirect T cells to eliminate specific autoantibody-producing B cells without causing broad immunosuppression. Utilizing anti-CD3 antibodies, the engineered engagers successfully activated T cells to specifically eradicate target B cells in preclinical models of autoimmune disease.”
2. A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies
Zhang Y, et al. Nat Commun. 2023 Mar 27;14(1):1664. PMID: 36973273
“Bispecific T cell engagers (BiTEs) have shown significant clinical efficacy, yet standard approaches often fail to fully exploit the unique properties of unconventional T cell populations. Researchers engineered a novel bispecific engager targeting CD1d and CD3, capable of simultaneously recruiting and activating both type 1 natural killer T (NKT) cells and Vγ9Vδ2-T cells against hematological malignancies. The incorporation of CD3 activation domains effectively triggered these specialized immune cells to exert potent cytotoxicity against CD1d-expressing tumor cells in vivo.”
3. CD3-immunotoxin mediated depletion of T cells in lymphoid tissues of rhesus macaques
Bergamaschi C, et al. JCI Insight. 2023 Oct 9;8(19):e170884. PMID: 37676694
“Achieving profound T cell depletion within lymphoid tissues remains a major challenge in solid organ transplantation and the treatment of severe autoimmune conditions. This investigation evaluated a novel recombinant CD3-immunotoxin designed to selectively ablate T lymphocytes directly within the lymph nodes and spleen of non-human primate models. Administration of this CD3-targeted therapy resulted in the rapid and sustained depletion of resident T cells across various lymphoid compartments, demonstrating its potential for robust immunomodulation.”
4. Cytomegalovirus mediates expansion of IL-15–responsive innate-memory cells with SIV killing function
Vargas-Inchausti C, et al. Front Immunol. 2021 Jul 21;12:695503. PMID: 34367156
“Cytomegalovirus (CMV) vectors have emerged as highly effective vaccine candidates capable of inducing unconventional, broadly protective immune responses against simian immunodeficiency virus (SIV). This study demonstrates that CMV infection drives the robust expansion of a unique population of IL-15-responsive innate-memory cells exhibiting potent SIV-killing capabilities. T cell functional assays and phenotypic characterizations, facilitated by cross-reactive CD3 antibodies, confirmed the enhanced antiviral effector functions of these specialized cellular subsets.”
5. A Novel SIV Gag-Specific CD4+ T-Cell Clone Suppresses SIVmac239 Replication in CD4+ T Cells Revealing the Interplay between Antiviral Effector Cells and Their Infected Targets
Mason RD, et al. J Virol. 2016 Jun 10;90(13):5999-6014. PMID: 27099307
“While CD8+ T cells are traditionally recognized for their antiviral cytotoxicity, the direct effector functions of CD4+ T cells in controlling retroviral replication are increasingly appreciated. Researchers isolated and characterized a novel SIV Gag-specific CD4+ T cell clone capable of profoundly suppressing the replication of SIVmac239 within infected target cells. Utilizing comprehensive cellular profiling, including T cell receptor activation via anti-CD3 monoclonal antibodies, the study elucidates the complex mechanistic interplay between antiviral CD4+ effector cells and their viral targets.”